Kahn, A. M., Du, J., Schellhorn, S., DiGiovanna, M., Kidwai, W., Rozenblit, M., O'Neil, D., Legare, R. D., Casasanta, N., Fischbach, N. A., Fenn, K. M., Blenman, K., Ortiz, C. N., Wei, W., Maues, J., Krop, I. E., Winer, E. P., Lustberg, M. B., Pusztai, L. (2026). Phase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164